Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre non-randomised open-label phase 1 trial of pembrolizumab given in
combination with SBRT to part of a pleural-based lesion in patients with unresectable MPM.
This study will recruit up to 18 patients whose MPM has progressed beyond first-line of
palliative chemotherapy, with a platinum-based doublet, and now requires further palliative
systemic treatment, or have declined first-line palliative chemotherapy, however must have
been considered suitable for a platinum doublet chemotherapy.